Maxim Group Reiterates a Buy Rating on Atai Life Sciences (ATAI) With a $10 PT

Atai Life Sciences (NASDAQ:ATAI) is one of the best strong buy penny stocks to buy now. On July 30, Maxim Group analyst Michael Okunewitch maintained a Buy rating on Atai Life Sciences (NASDAQ:ATAI), retaining the price target of $10.00.

The analyst supported the rating with Atai Life Sciences’ (NASDAQ:ATAI) solid potential and strategic positioning in the biopharmaceutical sector. He stated that although a recent study failed to meet its primary endpoint, it exhibited consistent numerical improvements in cognitive measures, which shows potential value in the program.

Okunewitch added that Atai Life Sciences (NASDAQ:ATAI) has a diversified portfolio strategy that mitigates risks associated with single assets, a beneficial factor in the volatile biotech industry.

He added that a core value driver for the company is its focus on its short-acting psychedelic pipeline, particularly in affective disorders. The promising data from these programs and supportive regulatory signals are significant factors bolstering investor confidence.

Headquartered in Germany, Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on treating mental health disorders.

While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.